State Street

Seth Coulson, CFA, Joins DoubleLine as Institutional Relationship Manager in Central U.S.

Retrieved on: 
Friday, March 1, 2024
Jeffrey Gundlach, PIMCO, Agency, CFA, State Street, University, Business administration, University of Wisconsin–La Crosse, Midwestern United States

TAMPA, Fla., March 1, 2024 /PRNewswire/ -- Seth Coulson, CFA, has joined DoubleLine Capital as a Relationship Manager for institutional investors and investment consulting firms in the Midwestern United States.

Key Points: 
  • TAMPA, Fla., March 1, 2024 /PRNewswire/ -- Seth Coulson, CFA, has joined DoubleLine Capital as a Relationship Manager for institutional investors and investment consulting firms in the Midwestern United States.
  • Mr. Coulson is based at DoubleLine's Los Angeles offices and reports to Ryan Hart, Director, Institutional, Global Relationship Management.
  • Prior to PIMCO, Mr. Coulson worked at State Street IMS in Irvine, Calif., where he led the allocations process for PIMCO's Agency mortgage-backed securities trades.
  • Mr. Coulson holds a Master of Business Administration, University of Southern California Marshall School of Business, Los Angeles, and a Bachelor of Science in Business Administration, Finance Major/Spanish Minor, University of Wisconsin-La Crosse.

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

Retrieved on: 
Thursday, February 29, 2024
Varick Street, Attention, SAN, Truist, Prospectus, Telephone, Stifel, File, 2nd Floor, Sale, Vikings, Form, State Street, SVB Securities, Therapy, Morgan Stanley, S-3, Security (finance), Oppenheimer Holdings

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share.

Key Points: 
  • SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $550.0 million.
  • Viking has also granted the underwriters a 30-day option to purchase up to 970,650 additional shares of its common stock.
  • All of the shares of common stock in the offering are to be sold by Viking.

Viking Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, February 27, 2024
Varick Street, Attention, SAN, Truist, Prospectus, Telephone, Stifel, File, 2nd Floor, Sale, Vikings, Form, State Street, SVB Securities, Therapy, Morgan Stanley, S-3, Security (finance), Research, Life insurance

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock.

Key Points: 
  • SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock.
  • Viking also intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock.
  • All of the shares of common stock to be sold in the proposed offering are to be sold by Viking.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

MIAMI INVESTOR SUMMIT KICKS OFF TODAY WITH GLOBAL LEADERS DISCUSSING HUMANITY'S BIGGEST CHALLENGES

Retrieved on: 
Friday, February 23, 2024
FII, Sustainability, Franklin Templeton Investments, Public policy, Blockchain, Artificial intelligence, Blackstone Inc., AI, Arm, Investment, Computer, Thought, Harvard University, Government, Education, Entrepreneurship, State Street, Bombardier Inc., Health care, Ministry of Investment, Future Investment Initiative Institute, Policy, Public Investment Fund, Dell Technologies, Papal conclave, Knowledge, Robotics, NEOM, Corcoran Group, Treasury, ACWA Power, GFH, HSBC, Renewable energy

MIAMI, Feb. 23, 2024 /PRNewswire/ -- Leading figures from finance, government, business, tech, and innovation are convening to deliberate on a range of pressing economic and public policy issues at FII PRIORITY Miami summit, a major global investor summit, held today and tomorrow at Miami's Faena Forum.

Key Points: 
  • MIAMI, Feb. 23, 2024 /PRNewswire/ -- Leading figures from finance, government, business, tech, and innovation are convening to deliberate on a range of pressing economic and public policy issues at FII PRIORITY Miami summit, a major global investor summit, held today and tomorrow at Miami's Faena Forum.
  • The summit brings together investors from around the world gathered with CEOs of major global corporations and policy experts to seek workable impactful solution to issues such as the regulation of AI.
  • The summit's much anticipated roundtable of global CEOs, entitled the "Board of Changemakers," discussed trends and economic outlook.
  • The FII PRIORITY Miami summit continues conversations held in Hong Kong and Riyadh in Autumn 2023.

MIAMI INVESTOR SUMMIT KICKS OFF TODAY WITH GLOBAL LEADERS DISCUSSING HUMANITY'S BIGGEST CHALLENGES

Retrieved on: 
Friday, February 23, 2024
FII, Sustainability, Franklin Templeton Investments, Public policy, Blockchain, Artificial intelligence, Blackstone Inc., AI, Arm, Investment, Computer, Thought, Harvard University, Government, Education, Entrepreneurship, State Street, Bombardier Inc., Health care, Ministry of Investment, Future Investment Initiative Institute, Policy, Public Investment Fund, Dell Technologies, Papal conclave, Knowledge, Robotics, NEOM, Corcoran Group, Treasury, ACWA Power, GFH, HSBC, Renewable energy

MIAMI, Feb. 23, 2024 /PRNewswire/ -- Leading figures from finance, government, business, tech, and innovation are convening to deliberate on a range of pressing economic and public policy issues at FII PRIORITY Miami summit, a major global investor summit, held today and tomorrow at Miami's Faena Forum.

Key Points: 
  • MIAMI, Feb. 23, 2024 /PRNewswire/ -- Leading figures from finance, government, business, tech, and innovation are convening to deliberate on a range of pressing economic and public policy issues at FII PRIORITY Miami summit, a major global investor summit, held today and tomorrow at Miami's Faena Forum.
  • The summit brings together investors from around the world gathered with CEOs of major global corporations and policy experts to seek workable impactful solution to issues such as the regulation of AI.
  • The summit's much anticipated roundtable of global CEOs, entitled the "Board of Changemakers," discussed trends and economic outlook.
  • The FII PRIORITY Miami summit continues conversations held in Hong Kong and Riyadh in Autumn 2023.

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 16, 2024
Attention, Prospectus, Telephone, Floor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, Madison Avenue, Guggenheim, Security (finance), Guggenheim Partners, Research

The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.

Key Points: 
  • The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.
  • Leerink Partners, Citigroup and Guggenheim Securities acted as joint bookrunning managers for the offering.
  • LifeSci Capital acted as lead manager for the offering.
  • The shares were offered pursuant to a shelf registration statement on Form S-3 (File No.

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 16, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Attention, Lexington Avenue, Prospectus, Telephone, File, Sale, Exercise, Form, State Street, Broadridge Financial Solutions, SVB Securities, Madison Avenue, Guggenheim, S-3, Guggenheim Partners, Security (finance)

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.

Key Points: 
  • Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.
  • The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are $230.0 million.
  • All of the shares in the offering were sold by Immunome.
  • J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities acted as joint book-running managers for the offering.

Azitra, Inc. Announces Closing of Public Offering

Retrieved on: 
Friday, February 16, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, ThinkEquity, State Street, Security (finance), Prospectus, Sale, Form, Research

Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.
  • Total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses, were approximately $5 million.
  • In addition, Azitra has granted the underwriters a 45-day option to purchase up to an additional 2,500,000 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.
  • A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov .

Beamr Imaging Ltd. Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

Retrieved on: 
Thursday, February 15, 2024
ThinkEquity, Prospectus, Marketing, Sale, Exercise, Form, BMR, State Street, Public expenditure, Security (finance), Research, Life insurance

Herzliya, Israel, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (Nasdaq: BMR) (“Beamr” or the “Company”), a leader in video optimization technology, today announced the closing of its previously announced public offering of 1,971,300 ordinary shares, including 257,100 shares sold upon full exercise of the underwriter's option to purchase additional shares, at a public offering price of $7.00 per share.

Key Points: 
  • Herzliya, Israel, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (Nasdaq: BMR) (“Beamr” or the “Company”), a leader in video optimization technology, today announced the closing of its previously announced public offering of 1,971,300 ordinary shares, including 257,100 shares sold upon full exercise of the underwriter's option to purchase additional shares, at a public offering price of $7.00 per share.
  • Total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses, were approximately $13.8 million.
  • 333-272257) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 12, 2024.
  • Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

Eltek Announces Closing of $10 Million Public Offering

Retrieved on: 
Thursday, February 15, 2024
ThinkEquity, State Street, Prospectus, Sale, Life insurance

PETACH TIKVA, Israel, Feb. 15, 2024 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, announced today the closing of its previously announced public offering of 625,000 ordinary shares at a public offering price of $16.00 per share, for gross proceeds of $10,000,000, before deducting underwriting discounts and offering expenses.

Key Points: 
  • PETACH TIKVA, Israel, Feb. 15, 2024 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, announced today the closing of its previously announced public offering of 625,000 ordinary shares at a public offering price of $16.00 per share, for gross proceeds of $10,000,000, before deducting underwriting discounts and offering expenses.
  • ThinkEquity acted as sole book-running manager for the offering.
  • The offering is being made pursuant to an effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (the "SEC").
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov .